DIRECT proof that ionizing radiation induces leukaemia in man does not exist, but there is a large body of suggestive evidence (Anderson et al., 1972;  Cronkite, Moloney and Bond, 1960; Report of the United Nations Scientific Committee, 1972) indicating that leukaemia, predominantly of the myeloid variety, may be induced in individuals exposed to ionizing radiation accidentally or for diagnostic or therapeutic reasons.
In very large series of patients (Pochin, 1961; Saenger, Thoma and Tompkins, 1968) treated with relatively low doses of 1311 for hyperthyroidism, no evidence has been found of an increased leukaemia risk which could be attributed to the treatment.
High doses of 131I have been employed in the treatment of thyroid carcinoma. Since 1953 a total of 11 cases of leukaemia arising in patients treated for thyroid carcinoma with 131I have been reported in 7 publications (Blom, Querido and Leeksma, 1955; Delarue, Tubiana and Dutriex, 1953; Jeliffe and Jones, 1960; Lewallen and Godwin, 1963; Ozarda, Ergin and Bender, 1961; Pochin, 1961; Seidlin et al., 1955) . The cases are ' The Radium Centre, Odense Hospital. 2 The 3The Radium Centre, Arhus Municipal Hospital, Arb summarized in Table I . Nine of the 11 patients quoted in the literature were women; all cases had developed within 5 years of the start of treatment and all cases were myeloid leukaemias. Unfortunately the total number of patients treated was mentioned in only 2 of these reports (Pochin, 1961; Seidlin et al., 1955) so that a combined estimate cannot be made of the leukaemia risk in the 7 treatment series. In Pochin's series of 215 patients (Pochin, 1969) 4 cases of leukaemia occurred compared with 0.08 cases expected during the observation period. This difference is highly significant.
MATERIAL AND METHODS
All cases of thyroid carcinoma treated with 131I in Denmark from 1948 until the end of 1972 were reviewed. All patients who had been given more than 50 mCi of 1311 were included in the material, consisting of 194 who had received from 50 to 1313 mCi of 131I during the course of their disease. All patients have been followed until death or until the end of the study. Delarue et al., 1953 Blom et al., 1955 Seidlin et al., 1955 Jeliffe et al., 1960 Ozarda et al., 1961 Pochin, 1961 Lewallen et at., 1963 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 (Clemmesen, 1964 (Clemmesen, , 1969 . Fig. 1 (Clemmesen, 1964 (Clemmesen, , 1969 . For the years 1963-72 the latest available incidence rates for 1963-67 (Clemmesen) were used for the calculations (Table II) .
To obtain an additional estimate of the risk of developing leukaemia after treatment with 1311, a brief questionnaire was sent to the 5 institutions which had reported cases of leukaemia arising after 1311 treatment without stating the total number of patients treated. It was asked how many patients had been treated with 131J in all, and whether further cases of leukaemia had been observed. At 27 years of age she had been treated for a thyroid ailment, probably a toxic goitre. The patient possibly had x-ray treatment of the thyroid gland, but records of the treatment(s) given in 1919 are not available. Otherwise she had always enjoyed good health.
In July 1967 a large bilateral nodular goitre w%Nas found which had grown slowly foi 5 vears. For the preceding 2 months the patient had been hoarse and subsequenitly a paralysis of the left recurrent nerv-e wNas demonstrated.
IIn August 1967 a sub-total thyroidectomy wa.s performed. A follicular carcinoma was found in the left lobe and a colloid goitre in the right lobe of the thyroid gland. The operationi was considered to be non-radical because the tumour was infiltrating the soft-part structures of the left side of the neclk. However, scanning studies with 1311 did not demonstrate pathological concentratioIns of the isotope in this region.
From September 1967 to February 1969 600 InCi of 1311 was administered in 6 doses and the patient was further treated with thvroid hormone. No clinical or scintigraphic evidence of recurrence of the thyroid carcinoma wNas found from the time of the operation and up to the death of the patient.
In July 1968 blood counts, which had prev-iously been entirely normal, showed HI) 9-9 g/100 ml, leucocytes 42,000/mm3, and platelets 1,800,000/mm3. The differential couInt showed 10% myelocytes, 18% bands, 540/ neutrophils, 90o eosinophils, 1% monocytes and 8% lymphocytes. A bone marrow study showed a typical picture of chronic mveloid leukaemia whereas an earlier bone mairow study before 131J treatment had been normal. There was no hepatic or spleinic enlargement.
The patient was placed on Myleran treatmeint which controlled the leukaemia effectively. In June 1969, however, the patient, who by then had become aged and frail, succumbed to an attack of gastroenteritis. She died at home and no autopsy was performed. (Ozarda et al., 1961) .
Although thyroid carcinoma is about 3 times inore frequent in women than in men (Gowing, 1970) , it is difficult to explain why only 2 of the 14 leukaemia cases were found in men. Data on radiation leukaemogenesis appears to show that in populations exposed to ionizing radiation more men than women develop leukaemia (Gibson et al., 1972 ; Report ofthe United Nations Scientific Committee, 1972). As pointed out by Pochin (Pochin, 1969 (Ozarda et al., 1961 ) that " we do not have to worry about the probabilitv of induced leukaemia since the life expectancy of these patients is not long enough for it to develop ". This statement is challenged by the fact that the median survival was 4 7 years in the present series in spite of the fact that 3300 of the patients were more than 70 years old (Fig. 1) . 37 of those living more than 4 years after the diagnosis of thyroid carcinoma had received a total dose of 1311 of less than 200 mCi. In most cases of thyroid carcinoma this dose must be considered to be too small to control metastatic disease, and the long survival of these patients must be ascribed to additional treatment such as surgery and/or external radiotherapy. The treatment with 1311 does not appear to have been justified in the majority of these patients, and they were thus exposed unnecessarilv to a treatment associated with an increased incidence of leukaemia.
There is no doubt that 1311 remains the treatment of choice in metastasizing, iodine-concentrating thyroid carcinoma. However, 1311 should not be the primary treatment of localized iodine-concentrating thyroid carcinoma which can be controlled by other treatments not associated with an increased incidence of leukaemia.
Dr Johannes Clemmesen, the Danish Cancer Registry, kindly placed the unpublished leukaemia incidence data for the years 1963-67 at our disposal. Thanks are due to Dr Merrill A. Bender, Roswell Park Memorial Institute, and to Dr Eugene P. Cronkite, Brookhaven National Laboratory, for the very helpful information given concerning the patients treated at these two institutions.
